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Abstract
Correct detection of extended-spectrum beta-lactamases (ESBLs) is crucial for infection control and antibiotic choice. We per-
formed a study to determine the cost-effectiveness of phenotypical testing, which can be inaccurate, and genotypical tests, which
are considered to be more reliable but also more expensive. All patients that had been in isolation in the Amphia hospital because
of the detection of ESBL according to the ESBL Etest were included in the survey. All strains were retested using the double disk
confirmation test (DDCT) and a genotypical method. This was a commercially available microarray (Check-Points). Discordant
results were confirmed by PCR and sequencing. In total 174 patients were included. In 24 of 174 (14%) patients, ESBL carriage
could not be confirmed with the microarray. This was verified with PCR and sequencing. The mean duration of isolation was
15 days, adding up to a total number of isolation days of 2571. False-positive results according to the microarray resulted in a
total of 279 days of unnecessary isolation for the Etest and 151 days for the DDCT. Using Etest to detect the presence of ESBL
results in a false-positive outcome in 14% of the cases. This results in unnecessary isolation of patients, which can be omitted by
using a genotypic method.
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The prevalence of extended-spectrum beta-lactamase (ESBL)
producing Enterobacteriaceae is increasing rapidly [1–3]. Infec-
tions with ESBL are associated with increased costs and mor-
tality [4]. The control of ESBL is difficult as the resistance
genes of these microorganisms are located on plasmids and
may be transferred between different bacterial species and
even different genera of Enterobacteriaceae [5]. According to
the Dutch guidelines for infection control all hospitalized
patients colonised with ESBL have to be placed in isolation in a
separate room [6]. The current national guideline for micro-
biological detection of ESBL in the Netherlands recommends
the use of phenotypical tests for confirmation of ESBL. These
tests are sometimes difficult to interpret and may lead to false-
positive tests, resulting in unnecessary isolation of patients and
possibly inappropriate treatment, leading to higher costs. Phe-
notypical testing takes at least 1 day to provide results.
Genotypical methods are considered to be more accurate,
can provide characterization of the ESBL genes and have the
potential to provide results on the same day.
Recently, a new diagnostic microarray for detection and
identification of ESBL in Enterobacteriaceae has become
available. Several studies have concluded that the diagnostic
microarray is superior to phenotypical methods. Sensitivity
for ESBL was comparable to or higher than phenotypic
methods, whereas specificity was consistently higher [7–10].
The microarray had almost the same sensitivity and specific-
ity as PCR with additional sequencing and was therefore
used as the standard for testing [11].
We wanted to determine the effect of false-positive phe-
notypic testing on infection control measures and also
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evaluate the cost-effectiveness of ESBL testing. This was
done to determine if implementation of a genotypical test is
warranted.
Methods
Patients who had been isolated because of ESBL from
November 2006 until August 2010 in Amphia Hospital in
Breda were included. The Amphia Hospital is a large teaching
hospital located in the south of the Netherlands. The pre-
sumed ESBL-positive strains had been stored at )70C.
Information about type of organism, interpretation of pheno-
typical test and duration of isolation was obtained from the
laboratory information system.
Primary phenotypic detection of ESBL
For species identification and susceptibility testing the
Vitek 2 system (bioMe´rieux, Marcy l’Etoile, France) was
used. According to the Dutch national guideline for ESBL
detection, classification of Enterobacteriaceae was done to
the presence of chromosomal AmpC beta-lactamases in
two groups. Presence of ESBL production was determined
using the ESBL Etest (bioMe´rieux) [12]. The hands-on time
and the turn-around time were, respectively, 15 min and
16 h.
Genotypic detection of ESBL
The strains that had been stored at )70C were recollected
and DNA isolation was performed using the QIAamp DNA
Mini Kit system (QIAGEN, Hilden, Germany).
The ESBL Array (Check-Points, Wageningen, the Nether-
lands) is supplied as a kit. It is designed to detect single
nucleotide polymorphisms (SNPs) of essential blaTEM and
blaSHV variants and the following blaCTX-M groups: blaCTX-M-1,
blaCTX-M-2, blaCTX-M-9 and blaCTX-M-8/25, as described by
Cohen Stuart et al. [7].
Microarray images are read using a microarray reader
(ArrayTube Reader; ClonDiag Chip Technologies, Jena,
Germany) connected to a computer running dedicated soft-
ware for analysis of the images. The software indicates
whether blaTEM, blaSHV, blaCTX-M or a combination of these
genes is present. The hands-on time and the turn-around
time were, respectively, 2 and 8 h.
Secondary phenotypic detection of ESBL
All strains were retested using the DDCT (Rosco diagnosti-
ca, Taastrup, Denmark). Interpretation of the test was car-
ried out according to the Dutch national guideline for the
detection of ESBL in Enterobacteriaceae [12]. The hands-on
time and the turn-around time were, respectively, 15 min
and 16 h.
Retesting of primary phenotypical test (Etest)
After testing the strains with the microarray, the false-posi-
tive results obtained using the primary phenotypical test
(Etest) were retested using the same test and the same algo-
rithm.
Verifying the reference test (microarray)
The beta-lactamase genes were characterized by PCR at the
VUmc, followed by sequencing (BaseClear, Leiden, the Neth-
erlands), as described by Naiemi et al. [13]. Sequences were
analysed with Bionumerics software (version 6.5; Applied
Maths, Sint-Martens-Latem, Belgium) and compared with
sequences in the NCBI database (http://www.ncbi.nlm.nih.
gov/BLAST) and Lahey (http://www.lahey.org/studies/).
Results
Primary phenotypical test (Etest)
In total, 174 patients were included based on the initial Etest
results. Among these strains, 97% were group I Enterobacte-
riaceae. The organisms are shown in (Table 1). The total
number of days in isolation was 2571. The average duration
of isolation was 15 days (range, 1–93; median, 10).
Genotypical test
All 174 phenotypical ESBL-positive strains were retested
using the microarray. The microarray detected at least one
ESBL-gene in 149 strains. Among the ESBLs there were 90
blaCTX-M-1, 33 blaCTX-M-9, 5 blaCTX-M-2-8-25 and 25 blaTEM/SHV.
There were four strains that contained multiple ESBL genes.
According to the microarray there were 25 false-positive
phenotypical tests, resulting in a positive predictive value of
86% for the Etest. In group I Enterobacteriaceae 12%
(n = 21) were discordant and showed a phenotypical positive
test, whereas the genotypical test was negative. In group II
Enterobacteriaceae 67% (n = 4) were discordant (Table 1).
Among the 25 false-positive results there were three
patients that were tested with the same bacterial species
twice. This was in different episodes of isolation. The total
number of isolation days of these false-positive tests was
279 days (Table 2).
Secondary phenotypical test (DDCT)
At retesting of the 174 strains, 161 tested ESBL-positive
using the DDCT. Among these 161 positive phenotypical
tests are 13 false-positive tests according to the microarray.
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Retesting of these strains with the DDCT led to the same
results.
Among these false-positive tests, eight out of 13 tests
were just over the cut-off. The DDCT had no false-negative
tests. The total number of isolation days of these false-posi-
tive tests was 151 days (Table 2).
Retesting of primary phenotypical test (Etest)
At retesting of the 25 strains that were false-positive with
the Etest, 20 tested ESBL-positive using the Etest and one
could not be interpreted because of overgrowth.
Verifying the reference test (microarray)
The results of PCR and sequencing did not show ESBL in
blaTEM/SHV in the 25 strains where the microarray could not
find any ESBL genes. The PCR for blaCTX-M showed PCR
product in seven out of 25 strains. Then sequence analysis of
the PCR product was done. In six strains, all Klebsiella oxytoca,
the PCR product was non-specific; these were blaOXY genes
and no ESBL genes were found. In one E. coli we found
blaCTX-M-8, which is an ESBL gene.
Discussion
Comparing the results of Etest with those of the microarray,
14% (n = 24) were discordant. In group I Enterobacteriaceae
12% (n = 20) of the strains were discordant and in group II
Enterobacteriaceae 67% (n = 4). This indicates that a larger
amount of group II organisms could increase the percentage
of discordant results.
As reported by others, the microarray is more accurate
than phenotypical tests. However, the microarray is more
expensive to perform. We quantified the number of false-
positive findings in clinical practice, which enabled us to esti-
mate the savings that can be achieved. This is based on the
reduction of the number of isolation days on the wards in
relation to the costs of the microarray.
In this study the total cost of retesting the 174 samples
(cost materials for DNA isolation and microarray) was c. €
6000. The total number of days of isolation that could have
been avoided was 279 days. This means that the additional
costs of an isolation day should be at least 22 euro to result
in a net savings. The costs of isolation may vary between
hospitals or countries but are likely to be substantially higher
than 22 euro in most settings. Changing to a cheaper ESBL
confirmation test or not performing one at all can make fur-
ther reductions in costs. This study does not provide enough
data for discussion of this subject.
We decided not to include the cost of laboratory labour
because this is highly dependent on throughput of tests and
differences in the salaries of technicians. To do so, one could
use the hands-on time of the phenotypical vs. the genotypical
test, which is respectively 15 vs. 120 min.
Because of the possible limitations of the microarray com-
pared with the gold standard, PCR and gene sequencing
were carried out. We retested the 25 strains in which the
microarray could not find any ESBL genes. In 24 strains,
results were consistent with PCR and sequencing. In one
strain the microarray showed a lack of sensitivity and did
not pick-up blaCTX-M-8. This gene is included in the kit and
after retesting the microarray did pick-up the blaCTX-M-8.
This lack of sensitivity did not have a major impact on this
study because both tests, DDCT and Etest tested positive
for this strain and the duration of this isolation episode was
only 5 days.
We also showed that the PCR has a lack of specificity for
blaCTX-M in K. oxytica; therefore all results should be verified
by gene sequencing. The false-positive results in the pheno-
typic assays are likely to be caused by hyperproduction of
the chromosomal K1 beta-lactamase or by effects of other
resistance mechanisms that are also inhibited by clavulanic
acid, for example Enterobacteriaceae carrying wild-type beta-
lactamase genes. Retrospectively, we could also determine
TABLE 1. Microorganisms found am-
ong positive primary phenotypical
test (Etest). Discordant results in
the phenotypical test compared
with the microarray. Classification
according to Group I and Group II
Enterobacteriaceae
Discordant results
Etest 14% DDCT 7%
Group I (n = 168) Escherichia coli 145 7 12% 3 5%
Klebsiella (pneumoniae 14, oxytoca 7) 21 11 4
Proteus mirabilis 2 2 1
Group II (n = 6) Enterobacter cloacae 4 2 67% 2 67%
Citrobacter freundii 2 2 2
TABLE 2. Performance and costs (material only) of differ-
ent diagnostic tools compared with the microarray, which









Etest € 25 € 4.350 2.571 +279
DDCT € 4 € 696 2.443 +151
Microarray € 33 € 5.742 2.292 –
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two misinterpretations that caused a false-positive result and
one strain with overgrowth that made the test uninterpret-
able.
It is remarkable that the DDCT did not lead to false-posi-
tive results when testing strains of K. oxytoca with blaOXY,
whereas the Etest did. In other strains the DDCT also had
fewer false-positive results than the Etest.
This indicates that the performance of the DDCT is bet-
ter than the Etest but this could be biased. When the DDCT
was used as the initial screening and the Etest as a confirma-
tory method it is possible that the Etest would have found
false-positive DDCT results. The low cost and more objec-
tive reading of the DDCT warrants a further prospective
evaluation of the DDCT. After retrospective correction for
the false-negative microarray result, among 12 false-positive
results in the DDCT there were eight tests in which the
result was just above the cut-off. Changing this cut-off slightly
for a positive test could result in a better performance but
this should be evaluated in a prospective clinical study.
A major drawback of the microarray is that it is not capa-
ble of picking up new and unknown ESBL genes that have
not been incorporated in the microarray. When genotypic
assays are to be implemented on a larger scale this should
be accompanied by prospective surveillance for the emer-
gence of new resistance mechanisms.
In conclusion, the currently used phenotypical tests to
detect ESBL have a relatively high rate of false-positive
results. The microarray provides more reliable results and
thereby avoids unnecessary isolation days. In our study the
additional cost of 1 day of isolation had to be at least € 22
for the microarray to be cost-effective and costs can be fur-
ther reduced by changing phenotypical confirmation. Also
the microarray can provide results more rapidly than pheno-
typic tests. Therefore, the microarray should be considered
for implementation in the routine diagnostic laboratory.
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